We are live on ! Find out more
GILD icon

Gilead Sciences

1,326 hedge funds and large institutions have $139B invested in Gilead Sciences in 2014 Q3 according to their latest regulatory filings, with 126 funds opening new positions, 465 increasing their positions, 615 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more first-time investments, than exits

New positions opened: 126 | Existing positions closed: 51

46% more funds holding in top 10

Funds holding in top 10: 164240 (+76)

20% more capital invested

Capital invested by funds: $116B → $139B (+$22.7B)

5% more funds holding

Funds holding: 1,2621,326 (+64)

24% less repeat investments, than reductions

Existing positions increased: 465 | Existing positions reduced: 615

36% less call options, than puts

Call options by funds: $2.53B | Put options by funds: $3.96B

Holders
1,326
Holders Change
+64
Holders Change %
+5.07%
% of All Funds
38.47%
Holding in Top 10
240
Holding in Top 10 Change
+76
Holding in Top 10 Change %
+46.34%
% of All Funds
6.96%
New
126
Increased
465
Reduced
615
Closed
51
Calls
$2.53B
Puts
$3.96B
Net Calls
-$1.43B
Net Calls Change
-$802M
Name Holding Trade Value Shares
Change
Change in
Stake
CWG
51
C WorldWide Group
Denmark
$488M +$449M +4,586,070 New
BlackRock
52
BlackRock
New York
$454M +$15.7M +160,269 +4%
OH
53
Orbis Holdings
Bermuda
$453M -$185M -1,888,276 -31%
MAA
54
Managed Account Advisors
New Jersey
$447M -$48.9M -499,014 -11%
Charles Schwab
55
Charles Schwab
California
$442M +$38M +387,571 +10%
CCI
56
Columbus Circle Investors
$439M -$67.5M -689,614 -14%
EVM
57
Eaton Vance Management
Massachusetts
$438M -$53.6M -547,510 -12%
Sumitomo Mitsui Trust Group
58
Sumitomo Mitsui Trust Group
Japan
$431M -$7.53M -76,900 -2%
O
59
OrbiMed
New York
$400M +$32.1M +327,400 +10%
Axa
60
Axa
France
$392M -$27.6M -282,012 -7%
VOYA Investment Management
61
VOYA Investment Management
Georgia
$390M +$10.5M +106,850 +3%
D.E. Shaw & Co
62
D.E. Shaw & Co
New York
$382M +$223M +2,273,925 +173%
GE
63
General Electric
Ohio
$379M -$179M -1,830,058 -34%
AIM
64
abrdn Investment Management
United Kingdom
$378M +$45.8M +467,736 +15%
Barclays
65
Barclays
United Kingdom
$378M +$183M +1,867,671 +110%
AAMU
66
Amundi Asset Management US
Massachusetts
$376M -$35.5M -362,957 -9%
BIM
67
BlackRock Investment Management
Delaware
$375M -$95.4M -973,868 -22%
TIM
68
Thornburg Investment Management
New Mexico
$373M -$72.2M -737,776 -17%
Prudential Financial
69
Prudential Financial
New Jersey
$368M -$1.33M -13,562 -0.4%
Bank of Montreal
70
Bank of Montreal
Ontario, Canada
$363M +$117M +1,190,662 +54%
BNP Paribas Financial Markets
71
BNP Paribas Financial Markets
France
$358M +$226M +2,305,625 +218%
Parnassus Investments
72
Parnassus Investments
California
$358M -$490 -5 -0%
TA
73
Teachers Advisors
New York
$326M -$39.8M -406,946 -12%
New York State Teachers Retirement System (NYSTRS)
74
New York State Teachers Retirement System (NYSTRS)
New York
$325M -$5.81M -59,358 -2%
Adage Capital Partners
75
Adage Capital Partners
Massachusetts
$321M -$21.3M -217,750 -7%

GILD Hedge Fund Activity: Q3 2014 in Review

1,326 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2014, worth a combined $139B — up 20% from $116B a quarter earlier.

Buyers outnumbered sellers: 126 funds opened new GILD positions and 51 closed out — a net gain of 75 holders — while 465 added to existing stakes and 615 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $226M. The largest seller was Capital Research Global Investors, cutting an estimated $1.52B.

  • 1,326 institutional investors held Gilead Sciences (GILD) as of Q3 2014, up from 1,262 in Q2 2014.
  • Funds reported $139B of Gilead Sciences stock for Q3 2014, up 20% quarter-over-quarter.
  • 126 funds opened new Gilead Sciences positions in Q3 2014 and 51 closed out, a net change of +75 holders.
  • The largest Gilead Sciences buyer in Q3 2014 was BNP Paribas Financial Markets, an estimated $226M added.
  • The largest Gilead Sciences seller in Q3 2014 was Capital Research Global Investors, an estimated $1.52B sold.

Based on aggregated 13F filings for Q3 2014.